Skip to main navigation Skip to search Skip to main content

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine Peters, Jennifer L. Clarke, Justin T. Jordan, John de Groot, Leia Nghiemphu, Thomas Kaley, Howard Colman, Christine McCluskey, Sarah Gaffey, Timothy R. Smith, David J. Cote, Mariano Severgnini, Jennifer H. Yearley, Qing Zhao, Wendy M. Blumenschein, Dan G. Duda, Alona Muzikansky, Rakesh K. JainPatrick Y. Wen, David A. Reardon

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Keyphrases